Oncology, viruses and aging treaments; bispecific antibodies, small molecules

Convalife Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative drugs targeting oncology, viral infections, and age-related diseases. The company aims to address unmet clinical needs both in China and globally by designing and developing original drugs with "First-in-Class" or "Best-in-Class" potential. Their product pipeline includes a range of therapies for various cancers, such as breast, lung, and pancreatic cancer, as well as blood cancers. Notable products in their pipeline include a second-generation PARP inhibitor, CVL218, and a highly selective dual inhibitor of PI3K β/δ, CVL237, which have shown promising potential in clinical settings.

In addition to oncology, Convalife is also engaged in drug development for infectious diseases, including treatments for COVID-19, respiratory syncytial virus, monkeypox, and yellow fever. The company emphasizes innovation through the integration of advanced technologies and collaboration with leading research institutions. Their commitment to sustainable innovation and resource integration is evident in their approach to drug discovery, which includes the application of artificial intelligence to accelerate the development of new therapies. Convalife's vision is to become a global leader in biopharmaceuticals by advancing health through collaborative and innovative scientific breakthroughs.

China

Convalife Pharmaceuticals is an innovative pharmaceutical company that specializes in drug research and development for tumor diseases. They are dedicated to developing innovative drugs and focus on antibody biopharmaceuticals and small molecule treatments.

Convalife Pharmaceuticals

Company Details